相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。A 3-Tier Chemotherapy Response Score for Ovarian/Fallopian Tube/Peritoneal High-grade Serous Carcinoma Is it Clinically Relevant?
Barrett C. Lawson et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2020)
Are polyploid giant cancer cells in high grade serous carcinoma of the ovary blastomere-like cancer stem cells
Alireza Salem et al.
ANNALS OF DIAGNOSTIC PATHOLOGY (2020)
Genomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromes
Guillermo Montalban-Bravo et al.
BLOOD ADVANCES (2020)
Assessment of a Chemotherapy Response Score (CRS) System for Tubo-Ovarian High-Grade Serous Carcinoma (HGSC)
Helena M. Ditzel et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY (2019)
Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient data
Paul A. Cohen et al.
GYNECOLOGIC ONCOLOGY (2019)
Measuring response to neoadjuvant chemotherapy in high-grade serous tubo-ovarian carcinoma: an analysis of the correlation between CT imaging and chemotherapy response score
Meabh McNulty et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2019)
DNA Damage Response and Repair Pathway Alteration and Its Association With Tumor Mutation Burden and Platinum-Based Chemotherapy in SCLC
Sehhoon Park et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
High NPM1 mutant allele burden at diagnosis correlates with minimal residual disease at first remission in de novo acute myeloid leukemia
Sanjay S. Patel et al.
AMERICAN JOURNAL OF HEMATOLOGY (2019)
Mutational burden and signatures in 4000 Japanese cancers provide insights into tumorigenesis and response to therapy
Keiichi Hatakeyama et al.
CANCER SCIENCE (2019)
Pathological Chemotherapy Response Score in Patients Affected by High Grade Serous Ovarian Carcinoma: The Prognostic Role of Omental and Ovarian Residual Disease
Angela Santoro et al.
FRONTIERS IN ONCOLOGY (2019)
Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic
T. A. Chan et al.
ANNALS OF ONCOLOGY (2019)
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
Robert M. Samstein et al.
NATURE GENETICS (2019)
Avoidance of apoptotic death via a hyperploid salvage survival pathway after platinum treatment in high grade serous carcinoma cell line models
Tony Yeung et al.
Oncotarget (2019)
High NPM1-mutant allele burden at diagnosis predicts unfavorable outcomes in de novo AML
Sanjay S. Patel et al.
BLOOD (2018)
Immunogenomic Analyses of Advanced Serous Ovarian Cancer Reveal Immune Score is a Strong Prognostic Factor and an Indicator of Chemosensitivity
Dapeng Hao et al.
CLINICAL CANCER RESEARCH (2018)
Biomarker Assessment of HR Deficiency, Tumor BRCA1/2 Mutations, and CCNE1 Copy Number in Ovarian Cancer: Associations with Clinical Outcome Following Platinum Monotherapy
Euan A. Stronach et al.
MOLECULAR CANCER RESEARCH (2018)
Landscape of genomic alterations in high-grade serous ovarian cancer from exceptional long- and short-term survivors
S. Y. Cindy Yang et al.
GENOME MEDICINE (2018)
A Targeted High-Throughput Next-Generation Sequencing Panel for Clinical Screening of Mutations, Gene Amplifications, and Fusions in Solid Tumors
Rajyalakshmi Luthra et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2017)
Genomic consequences of aberrant DNA repair mechanisms stratify ovarian cancer histotypes
Yi Kan Wang et al.
NATURE GENETICS (2017)
Comprehensive Analysis of Hypermutation in Human Cancer
Brittany B. Campbell et al.
CELL (2017)
Chemotherapy Response Score: Development and Validation of a System to Quantify Histopathologic Response to Neoadjuvant Chemotherapy in Tubo-Ovarian High-Grade Serous Carcinoma
Steffen Boehm et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
TP53 mutations, tetraploidy and homologous recombination repair defects in early stage high-grade serous ovarian cancer
Jeremy Chien et al.
NUCLEIC ACIDS RESEARCH (2015)
Tumor Mutation Burden Forecasts Outcome in Ovarian Cancer with BRCA1 or BRCA2 Mutations
Nicolai Juul Birkbak et al.
PLOS ONE (2013)
A DNA Repair Pathway-Focused Score for Prediction of Outcomes in Ovarian Cancer Treated With Platinum-Based Chemotherapy
Josephine Kang et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2012)
Integrated genomic analyses of ovarian carcinoma
D. Bell et al.
NATURE (2011)
Role of Surgical Outcome as Prognostic Factor in Advanced Epithelial Ovarian Cancer: A Combined Exploratory Analysis of 3 Prospectively Randomized Phase 3 Multicenter Trials By the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO)
Andreas du Bois et al.
CANCER (2009)
Grading ovarian serous carcinoma using a two-tier system
A Malpica et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2004)
Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer
L Zhang et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
分享论文
